PuraMed BioScience (OTCBB: PMBS) Migraine Treatment Now Available at CVS, the 2nd Largest Drug Chain in the United States

Northern, WI 1/25/12 (StreetBeat) -- PuraMed BioScience, Inc. (OTCBB: PMBS) announced today that LipiGesic M, their clinically proven effective and safe, all natural product for the treatment of migraine headaches, is now available for purchase at CVS, the 2nd Largest Drug Chain in the United States. With the addition of over 7,000 CVS locations, LipiGesic®M is now available in approximately 15,000 stores nationwide.

"We are pleased to now have our LipiGesic®M product available in both the #1 and #2 Drug Chain stores in the United States. Between the nearly 8,000 Walgreens and 7,000 CVS locations nationwide, we believe our product is gaining the exposure needed to generate significant revenue," stated Russ Mitchell, CEO of PuraMed BioScience.

PuraMed BioScience, Inc. anticipates announcing additional distribution in chain drug stores in the near future.

StreetBeat Disclaimer

Distributed by Viestly

ACI Worldwide's (Nasdaq: ACIW) Automated Check Management Selected by CVS/pharmacy

Tallahassee, FL 1/23/12 (StreetBeat) -- ACI Worldwide, Inc. (Nasdaq: ACIW), a leading international provider of payment systems, has announced that CVS/pharmacy (NYSE: CVS) has deployed ACI Retail Commerce Server(TM) for Check Management, in its 7,300 stores across the U.S., enabling the retail pharmacy chain to automate and reduce the cost of check authorization. CVS/pharmacy's deployment of ACI Retail Commerce Server is managed by ACI On Demand, ACI Worldwide's hosted service.

Retail Commerce Server authorizes check transactions locally based on the customer check writing history, and also manages thresholds and velocity limits set with the application -- rather than paying a third-party fee for each check authorized. Retail Commerce Server interfaces with third-party check guarantee processors to provide an additional layer of protection if required for customers who have no previous check writing history at CVS/pharmacy. The new system replaces CVS/pharmacy's previous paper-based check systems.

CVS/pharmacy serves approximately 5 million customers per day in its stores. The scale of the organization and the number of stores meant that managing the solution centrally using ACI On Demand hosting was ideal, because the check management and collections can be updated in the future without impacting the stores.

Ralph Dangelmaier, president of global markets and services at ACI Worldwide, said, "CVS/pharmacy explored a number of different solutions to solve its check authorization challenge, and I am delighted that the company selected Retail Commerce Server. The system is live today and delivering real benefits and savings every time it is used."

ACI Retail Commerce Server is an integrated software solution to acquire, authenticate, route, switch and authorize financial transactions across multiple channels. Retail Commerce Server provides a full range of functionality to support payment transactions -- both traditional, mainstream transactions, such as debit and credit at the point of sale (POS), as well as newer types of transactions, which include mobile commerce and internet banking.

It offers a comprehensive electronic payment and authorization system that facilitates a broad range of business applications, including automated clearing house (ACH); check and refunds authorization; credit, debit and electronic benefits transfer (EBT) processing; phone card activation; value card fulfillment; issuance and redemption; and loyalty cards and program management.

With the ACI On Demand management environment, organizations can access the same software and expertise enjoyed by more than 800 customers around the globe with significant reductions in overall IT expenses.

StreetBeat Disclaimer

Distributed by Viestly

PuraMed BioScience Inc. Announces Migraine Medicine Purchase Orders From CVS Pharmacy

Tallahassee, FL 12/6/11 (StreetBeat) --PuraMed BioScience Inc. (OTCBB:PMBS) announced today that it has received an initial series of purchase orders for its new over-the-counter migraine medication, LipiGesic(R)M with the second largest chain drug retailer in the United States, CVS (NYSE:CVS). This follows a recent announcement that LipiGesic(R)M is now available nationwide at Walgreens, the largest chain of drug stores in the United States.

CVS has over 7,000 locations in the United States which will almost double the amount of stores that will carry their featured product, LipiGesic(R)M, bringing the total number of stores to over 14,700. "This is a very exciting time for our Company," said Russ Mitchell, CEO of PuraMed BioScience. "In just the past few months, we have been able to announce purchase orders with the #1 and #2 chain drug stores in the U.S. Adding 7,000 CVS stores nationwide will nearly double our national exposure and dramatically affect our ability to reach even more migraine sufferers. While we are elated to have achieved this impressive level of national distribution, we will continue to actively pursue additional retail opportunities worldwide."

PuraMed expects to ship product to CVS in the beginning of January 2012 and anticipates it will begin to appear on shelves sometime around the end of January.

In addition to purchase orders of LipiGesic(R)M from both Walgreens and CVS, PuraMed also recently announced that three top headache researchers performed a study of LipiGesic(R)M that was published in the top-tier medical journal, Headache Volume 51, Number 7, July/August 2011. This study demonstrated that the product was highly effective and recommended LipiGesic(R)M as a first line treatment for migraines to the medical community.

PuraMed BioScience, Inc. plans to provide more information as it becomes
available.

StreetBeat Disclaimer

Distributed by Viestly

LargeCap Stocks to Watch Today

CVS said fourth-quarter income from continuing operations fell about 2% to $1.03 billion, or 75 cents a share, from $1.05 billion, or 74 cents a share, a year earlier. Earnings from continuing operations on an adjusted basis were 80 cents a share. Net revenue for the quarter fell 4.1% to $24.8 billion, down from $25.8 billion a year ago. Same-store sales increased 1.7% year over year. Wall Street was calling for earnings of 79 cents a share on revenue of $24.95 billion. Shares of CVS fell 1.6% to $34.10 in early trading Thursday.

BJ's Wholesale Club said Thursday it is exploring and evaluating strategic alternatives, including a possible sale of the retailer. Shares of BJ's surged 12.5% to $48.40 in premarket trading Thursday.

Merck posted a fourth-quarter loss of $531 million, or 17 cents a share, a reversal from year-earlier net income of $6.49 billion, or $2.35 a share. The quarter was impacted by purchase accounting adjustments, restructuring costs and merger-related costs. Excluding items, fourth-quarter earnings were 88 cents a share. Sales rose 20% to $12.09 billion from $10.09 billion the year before. Analysts, on average, were expecting earnings of 83 cents a share on revenue of $11.52 billion. Given industry pressures such as greater E.U. austerity measures and the additional impact of U.S. health care reform, and developments in its vorapaxar clinical program, the company withdrew its previous long-term target of high single-digit non-GAAP EPS compound annual growth from 2009 to 2013. Shares of the company fell 1.9% to $33.17 in premarket trading Thursday.

Dow Chemical said fourth-quarter earnings topped analysts' expectations as sales rose in emerging markets. The stock rose 2.8% to $37.65 in early trading Thursday.

Royal Dutch Shell said fourth-quarter profit skyrocketed as the oil company increased production, but stripping out items the result missed analysts' expectations. Shares of the company were unchanged at $71.18 in premarket trading.

Green Mountain Coffee Roasters blew past Wall Street's profit expectations for its fiscal first quarter. Shares of GMCR were surging 15.3% to $38.01 in premarket trading.


Santander's fourth-quarter profit tumbled 4.6%, weighed down by weak performance in Europe. The stock was falling 2.2% to $12.26 early Thursday.

Unilever said fourth-quarter net profit rose 15% to €1.04 billion, while sales rose 12% to €10.82 billion, driven by strong volume growth in the emerging markets. The company cautioned that it was facing "intense competition and the return of commodity cost volatility." Unilever was down 0.2% to $29.89.

Distributed by IntelBuilder Social Media Platform